Knowledge Centre

Bactobio is pioneering the discovery of novel antibiotics and fungicides by exploring the vast, uncharted world of uncultured microorganisms—bacteria that exist in soil but have never been studied in the lab.

Oxford-based Greywolf Therapeutics is developing new treatments for cancer patients who currently have limited immunotherapy options. With support from Innovate UK’s Biomedical Catalyst and Cancer Therapeutics programmes, the company is focusing on colorectal cancer, the UK’s fourth most common cancer and second leading cause of cancer-related death.

Sheffield-based MetalloBio, in partnership with the School of Science and Technology and Medical Technologies Innovation Facility at Nottingham Trent University (NTU), is developing a new class of antimicrobial agent using an innovative inorganic chemistry approach.

Oxford-based Ufonia, with support from the Innovate UK Biomedical Catalyst programme, is using AI to automate routine clinical consultations to make health and care accessible to everyone at any time.

Sheffield-based Rinri Therapeutics, supported by the Innovate UK Biomedical Catalyst, is developing a therapy to treat sensorineural hearing loss, which could reconnect millions of people worldwide with their families, friends and communities.

The mission of Oxford-based, Cancer Research UK spin-out, Infinitopes, is to prevent cancer deaths by tackling the leading cause: Metastases.

Theolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.

Join us to explore textile industry water consumption and discover innovative examples from Africa, Asia and the UK.

Wiltshire-based ALPS Ecoscience is redefining performance in the biogas sector, achieving a 30% uplift in biomethane production compared to industry standards. With tailored innovation and growth support from Innovate UK, the company has reached £1 million in turnover, signed its first international licensing agreement and is in active discussions with partners across Europe.

London-based digital therapeutics innovator, my mhealth, is transforming chronic disease management across the UK and US. Now supporting over 160,000 users in the UK, it is on track to reach more than half a million globally within the next three years. With tailored innovation and growth support from Innovate UK, the company has scaled from a team of 4 to 30 and launched fully commercial products on both sides of the Atlantic.